Anja Schmidt

Y‐box factor YB‐1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI‐1

Martin Janz, Nadia Harbeck, P. Dettmar et al. · International Journal of Cancer · 2001 · 182 citations · Full text

In‐field gait retraining and mobile monitoring to address running biomechanics associated with tibial stress fracture

Richard W. Willy, L. Buchenic, K. Rogacki et al. · Scandinavian Journal of Medicine and Science in Sports · 2015 · 169 citations

FVIII-specific human chimeric antigen receptor T-regulatory cells suppress T- and B-cell responses to FVIII

Jeongheon Yoon, Anja Schmidt, Ai-Hong Zhang et al. · Blood · 2016 · 138 citations · Full text

Engineered regulatory T cells expressing myelin-specific chimeric antigen receptors suppress EAE progression

Alessandra de Paula Pohl, Anja Schmidt, Ai-Hong Zhang et al. · Cellular Immunology · 2020 · 79 citations

Autoimmune Disease, Adaptive Immune System, Medicine +12

Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia

Thoralf Lange, Sylvia Wystub, Jacqueline Maier et al. · Leukemia · 2012 · 67 citations

Hematological Malignancy, Tumor Biology, Imatinib Treatment Differ +8